Suppressive effect of modified dominant negative RAS mutant on human cancer by gene transfer with non-viral vector

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1487-1491

  Suzuki, Hayato ^a,c   Kuzumaki, Satoshi ^b   Nakagawa, Koji ^a   Takimoto, Masato ^a   Shichinohe, Toshiaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenovirus vector; Dominant negative mutant; Gene therapy; H Ras; Human cancer; HVJ envelope; Non viral vector

Indexed keywords

N116Y PROTEIN; RAS PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; COLON CANCER; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; FEMALE; GENE; GENE DELETION; GENE FUNCTION; GENE TRANSFER; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; N116Y GENE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE H RAS; PANCREAS CANCER; PARAINFLUENZA VIRUS 1; TONGUE CANCER; UTERINE CERVIX CANCER; VIRUS ENVELOPE;

EID: 33846963829     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3298     Document Type: Article

References (28)

1. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am 1998; 12:595-615.
2. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, Hizuta A, Yasuda T, Roth JA, Tanaka N. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997; 73:367-70.
3. Kobayashi T, Sawa H, Morikawa J, Zhang W, Shiku H. Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells. Jpn J Cancer Res 2000; 91:1264-8.
4. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, Prieto J. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999; 6:514-22.
5. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Ojima T, Yamaue H. Improvement of carcinoembryonic antigen- specific prodrug gene therapy for experimental colon cancer. Surgery 2003; 133:309-17.
6. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A, Lawrence TS. The potential of 5-fluorocytosin /cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 2002; 9:844-9.
7. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63:3370-7.
8. Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther 1994; 1:403-7.
9. Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 1996; 66:125-30.
10. Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 1998; 78:366-71.
11. Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000; 7:518-26.
12. Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takiguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells. Cancer Lett 2000; 149:195-202.
13. Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. Int J Cancer 2001; 92:712-7.
14. Sakai N, Ogiso Y, Fujita H, Watari H, Koike T, Kuzumaki N. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp Cell Res 1994; 215:131-6.
15. Ogiso Y, Hwang YW, Shih TY, Kuzumaki N. Biological activity of a K-ras mutant that contains the 12R/59T/116Y mutations. Cancer Lett 1993; 75:19-26.
16. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-14.
17. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989; 57:1167-77.
18. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990; 63:133-9.
19. Hwang YW, Zhong JM, Poullet P, Parmeggiani A. Inhibition of SDC25 C-domain-induced guanine-nucleotide exchange by guanine ring binding domain mutants of v-H-ras. J Biol Chem 1993; 268:24692-8.
20. Shinohara N, Ogiso Y, Tanaka M, Sazawa A, Harabayashi T, Koyanagi T. The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines. J Urol 1997; 158:901-8.
21. Chen C, Dickman MB. Dominant active Rac and dominant negative Rac revert the dominant active Ras phenotype in Colletotrichum trifolii by distinct signalling pathways. Molecular Microbiology 2004; 51:1493-507.
22. Chung CY, Lee S, Briscoe C, Ellsworth C, Firtel RA. Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. Proc Natl Acad Sci USA 2000; 97:5225-30.
23. Ferrell Jr JE. MAP kinases in mitogenesis and development. Curr Top Dev Biol 1996; 33:1-60.
24. Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling-mechanisms and consequences. Curr Opin Genet Dev 2002; 12:30-5.
25. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286:1358-62.
26. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137:481-92.
27. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. Hemagglutinating Virus of Japan (HVJ) envelope vector. Mol Ther 2002; 6:219-26.
28. Hirano T, Fujimoto J, Ueki T, Yamamoto H, Iwasaki T, Morishita R, Sawa Y, Kaneda Y, Takahashi H, Okamoto E. Persistent gene expression in rat liver in vivo by repetitive transfection using HVJ-liposome. Gene Ther 1998; 5:459-64.